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Abstract Blastocystis is an enteric parasite that inhabits the
gastrointestinal tract of humans and many animals. This
emerging parasite has a worldwide distribution. It is often
identified as the most common eukaryotic organism reported
in human fecal samples. This parasite is recognized and diag-
nosed more often than ever before. Furthermore, some strains
develop resistance against currently recommended drugs,
such as metronidazole; therefore, the use of natural remedies
or special diets has many positive aspects that may address
this problem. The goal of this review is to compare natural
treatments and various diets against the efficacy of drugs, and
describe their influence on the composition of the gut micro-
biota, which affects Blastocystis growth and the occurrence of
symptoms. This article reviews important work in the litera-
ture, including the classification, life cycle, epidemiology,
pathogenesis, pathogenicity, genetics, biology, and treatment
of Blastocystis. It also includes a review of the current knowl-
edge about human gut microbiota and various diets proposed
for Blastocystis eradication. The literature has revealed that
garlic, ginger, some medical plants, and many spices contain
the most effective organic compounds for parasite eradication.
They work by inhibiting parasitic enzymes and nucleic acids,
as well as by inhibiting protein synthesis. The efficacy of any
specific organic compound depends on the Blastocystis sub-
type, and, consequently, on its immunity to treatment. In con-
clusion, the article discusses the findings that human gut mi-
crobiota composition triggers important mechanisms at the
molecular level, and, thus, has a crucial influence on the par-
asitic pathogenicity.
Meet Blastocystis sp.: classification and life cycle
Blastocystis is a unicellular protist present throughout the
world in the intestines of both healthy and symptomatic
humans and animals [1]. Its pathogenic potential is still con-
troversial [2–5]. For many years, it has been suggested that
Blastocystis is a commensal organism living in the human
intestine. Originally, the parasite was considered to be a harm-
less yeast until the 1970s, when evidence showed that
Blastocystis was actually a protist [6], belonging to the
Stramenopiles line of eukaryotic organisms. In 2009, Irikov
et al. [7] proposed to place this organism in a separate sixth
kingdom named BChromista^. Until recently, the taxonomy of
Blastocystis was based on the host from which it was isolated
(B. hominis from humans, B. ratti from rats, etc.). Modern
phylogenic studies have identified a lack of host specificity
for B. hominis and B. ratti, and, therefore, have proposed to
summarize the name as BBlastocystis species^, with different
ribosomal lineages classified into specific subtypes [8, 9].
Morphologically indistinguishable phylogenetic inferences
from small subunit rDNA (SSU rRNA) gene sequence analy-
ses revealed considerable genetic divergence among
Blastocystis isolated from humans and animals, with a total
of 17 subtypes being identified so far [10]. The majority of
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human Blastocystis carriage is attributable to ST3 [11, 12],
appearing quite rarely in non-primate hosts, suggesting that
ST3 may be the only subtype (ST) of human/primate origin
[13]. Several STs of supposed animal origin are zoonotic, with
the ability to infect humans at different frequencies. Therefore,
a higher risk of Blastocystis infection has been shown in peo-
ple living in rural areas and/or with close animal contact [14].
Phylogenetic trees comparing Blastocystis SSU rDNA se-
quences have been developed by many researchers in many
countries [11, 15, 16]. The trees are mostly created using the
neighbor-joining method (with the maximum composite like-
lihood model) based on either complete SSU rRNA genes or
the hypervariable region at the 5′-end of the SSU rRNA gene.
Relationships among Blastocystis subtypes occurring in
humans have been analyzed and groups of STs were named
as clades. One clade consists of STs 1, 2, and 5 (the closest
relation between ST1 and ST2); another clade consists of STs
3, 4, and 8 (the closest relation between ST3 and ST8). A third
clade consists of STs 6, 7, and 9 (where the closest relation is
between STs 6 and 9) [8, 11].
The parasite has been known since the early 1900s [1], but
only in the last decade has the biology and pathogenicity of
this parasite undergone more intensive studies. However, the
lack of standardization in detection techniques and methods
for molecular characterization has led to confusion and mis-
interpretation of the data. A number of studies suggested a
linkage between Blastocystis and gastrointestinal disorders,
skin symptoms, and many other problems. Recent epidemio-
logical data demonstrate the association of Blastocystis with a
variety of disorders [1, 17], such as diarrhea, abdominal pain,
fatigue, constipation, flatulence, chronic gastrointestinal ill-
nesses (irritable bowel syndrome, IBS), and skin rash or urti-
caria [18, 19]. Blastocystis has been found in both patients
with gastrointestinal symptoms and asymptomatic individuals
[20, 21]. According to a number of studies, the life cycle of
Blastocystis and its pathogenic aspects are still unclear.
Blastocystis infects at least 5–15% of individuals in devel-
oped countries and 50–100% of individuals in developing
countries [22, 23]. The difference can be partly explained by
poor hygiene practices and consumption of contaminated wa-
ter or food in developing countries [24]. The fecal–oral route
is considered to be the main mode of transmission.
Controversy regarding the commensal or pathogenic nature
of the infection has not changed for decades. Many case re-
ports and epidemiological andmicrobiological studies support
a pathogenic role of Blastocystis in causing intestinal inflam-
mation and urticarial symptoms [25], while there are many
reports on asymptomatic colonization by Blastocystis [26,
27]. Other aspects, including mode of transmission, pathoge-
nicity, life cycle, and molecular biology, remain largely
unclear.
The prevalence of Blastocystis infection is higher than that of
other intestinal parasites, such as Giardia, Entamoeba, or
Cryptosporidium [4]. In immunocompromised individuals, such
as those with human immunodeficiency virus (HIV) infection,
the prevalence of Blastocystis is between 30 and 38% in devel-
oped countries [28, 29]. It is suggested that Blastocystis is linked
with diarrhea in immunocompromised hosts, such as HIV-
infected persons, and nutrition statusmay be one of the important
risk factors associated with co-infections [3]. Children and the
elderly appear to be highly susceptible to Blastocystis infection
[30, 31], while other researchers have suggested that people be-
tween 30 and 50 years of age are most prone to being infected by
Blastocystis [32–34].
Six different morphological forms of the parasite have been
reported (vacuolar, granular, amoeboid, avacuolar,
multivacuolar, and cystic), with the cyst being the infective
stage and the amoeboid form supposedly playing a more ac-
tive role in the development of clinical manifestations [35].
The vacuolar form is most commonly observed in both labo-
ratory culture and stool samples [36, 37].
The life cycle and transmission of the parasite are still un-
der intensive investigation. Two types of reproduction have
been described: asexual reproduction by binary fission and
sexual reproduction by autogamy to form a primary cyst [3,
38], which is the only transmissible form of Blastocystis [39].
After getting into the intestinal lumen, the cysts first develop
into the vacuolar form. In humans, vacuolar forms divide by
binary fission and may develop into amoeboid, multivacuolar,
or granular forms, before they become pre-cyst [9]. Vacuolar
forms undergo encystation in the host intestine, while inter-
mediate cyst forms may be surrounded by a thick fibrillar
layer that is subsequently lost during passage into the external
environment to infect other individuals. The pre-cyst may also
develop into the thin-wall cyst and lead to autoinfection of the
host [9]. Information about the transformation from the amoe-
boid to the vacuolar form and from the vacuolar to the cyst
form is lacking.Blastocystis is a strict anaerobe and a common
inhabitant of the human gastrointestinal tract, as well as other
mammals. Many reports suggest that humans are potentially
infected by five or more subtypes ofBlastocystis [40], and that
certain animals represent reservoirs for transmission to
humans [1].
Genetic diversity and pathogenicity ofBlastocystis sp.
Based on SSU rDNA analysis, at least 17 different STs of
Blastocystis were detected, which colonize a wide range of
hosts, including humans and animals, both mammalian and
non-mammalian. Some STs exhibit host specificity with var-
iable geographic distribution. There is a high prevalence of
ST1 and ST2 in America, ST1 and ST3 in Australia,
Europe, and South Eastern Asia, and ST4 in Europe [8].
Humans are colonized mainly by ST1 through ST4, compris-
ing over 90% of reports; however, depending on the regions
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and countries, infection by ST5 through ST9 is also observed
[8, 41]. To date, ST10 through ST17 have not been found in
humans [11, 41], with the exception of research by Ramírez
et al. [42] in 2016, who reported, for the first time, human
infection with ST12. Gender differences in the prevalence of
Blastocystis STs have been reported. In Sweden, for instance,
ST3 was found to be more common in males than in females,
while in females, ST4 was almost as common as ST3.
However, the difference in the relative frequency of ST4 be-
tween men and women was statistically insignificant [43].
In the recent literature, researchers have been debating over
the correlation between distinct Blastocystis subtypes and
their pathogenic potential. Clark was the first to suggest that
different subtypes with different pathological potentials may
exist [43]. With respect to that fact, in 2000, Kaneda et al. [27]
suggested that STs 1, 2, and 4 might be responsible for gas-
trointestinal symptoms. In 2012, Poirier et al. [44] indicated
that ST7 is correlated with IBS. Puthia et al. [45] have shown
that, in rat epithelial cells, ST4 can induce apoptosis in a
contact-independent manner to increase epithelial permeabil-
ity. ST7 likely uses hydrolases to attack host tissues for its
nutrient supply [44]. In 2006, Yan et al. [46] demonstrated
only ST1 in a group of symptomatic patients, which was later
confirmed by El Safadi et al. [47] in 2013, demonstrating that
ST1 was associated with an elevated pathogenicity. The path-
ogenicity of ST4 was also hypothesized by Stensvold et al.
[48] in a short report in 2011. The explanations for pathoge-
nicity may include intra-subtype differences in Blastocystis
protease activity, variations in intestinal microbiota of the in-
dividual host, and a symbiotic role for viruses associated with
Blastocystis, which can interact to mediate host colonization
and Blastocystis virulence [49, 50]. Also, the presence of gut
microbiota seems to be essential for the pathogenic expression
of enteric protozoan such as Blastocystis. The hypothesis of
protozoa axenization by some bacteria has been proposed
[51]. The cysteine proteases produced by ST4 and ST7 were
revealed to be able to cleave human IgA in vitro [52, 53], as a
mechanism for parasite survival and colonization in the gut,
immune evasion, virulence, and cell cycle regulation [53].
Enzymes can also modulate inflammatory IL-8 production,
as well as cathepsin B activation [54], and are able to increase
the permeability of intestinal epithelial cells [45, 55].
In contrast, several studies showed no distinct differences
in STs between isolates from symptomatic and asymptomatic
groups of individuals with gastrointestinal disorders [39]. In
addition to unspecific gastrointestinal symptoms, an associa-
tion between the parasite subtypes and certain cutaneous dis-
orders have been observed [56–59], such as the presence of
Blastocystis ST2 [57], ST3 especially the amoeboid form, or
ST4 in patients with acute or chronic urticaria (CU) [56, 58,
60–62]. Oxidative stress is probably is another reason why
certain Blastocystis subtypes are more virulent. It is reported
that Blastocystis infection correlates with a significant
oxidative burst, leading to oxidative stress [63]. Some sub-
types may induce higher concentrations of oxidative stress
and precipitate skin reactions such as urticaria. A recent study
showed that live Blastocystis parasites and whole cell lysate
alone did not activate toll-like receptors in the human TLR
reporter monocytic cell line, while live ST4-WR1 parasites
inhibited the LPS-mediated NF-κB activation. In contrast,
whole cell lysates of ST7-B and ST4-WR1 induced pleiotro-
pic modulation of ligand-specific TLR-2 and TLR-4 activa-
tion, with a compounding effect of ST7-B on LPS-mediated
NF-κB activation [63]. A higher caspase-like activity of
Blastocystis spp. ST3 was found in isolates from individuals
who had gastrointestinal symptoms [65].
The human gut microbiota: current knowledge
The human microbiota is made up of different microbial com-
munities present in different parts of the human body, such as
the skin, vagina, oro-nasal cavity, esophagus, and gastrointes-
tinal (GI) tract [66]. The human body is composed of about
1013 cells [67]. There are about ten times this number of mi-
crobial cells associated with the healthy human body [67].
These microbes interact with their host and have an impact
on human health. The human GI microbiota is mostly concen-
trated in the colon and is made up of a majority of bacteria, a
few archaea, known as the microbiome, viruses (the virome),
fungi, and other uni- and multicellular eukaryotes, called pro-
tists and helminths, respectively [5, 68]. Only 30% of the
human GI microbiota have been characterized [69]. It is dif-
ficult to describe the actual meaning of Bnormal^ or Bhealthy^
human GI microbiota. A Bcore microbiota^ has been
established [70], but it remains unclear what the essential con-
stituents are. A number of studies have emphasized that the
distribution of specific microbial communities among individ-
uals could be influenced by several factors, including the geo-
graphical origin, age, diet of the studied individual, gender
[71], stress, smoking, GI infections, as well as antibiotic or
probiotic uptake [70, 72–78]. It is believed that the highly
evolved biofilm communities that are closely associated with
the intestinal epithelium are biologically more relevant than
planktonic microbes that exist in the lumen of the gut or as-
sociated with food residue [79]. Furthermore, fecal specimens
may not accurately portray the mucosal microbiota [72, 80].
And, also, there are significant differences between the micro-
biota of the liquid fraction compared with that associated with
the solid phase [79].
The gut microbiota is typically dominated by bacteria and
specifically by members of the divisions Bacteroidetes and
Firmicutes [81]. From stomach to colon, the bacterial biomass
ranges from 102–3 to 1011–12 cells/mL [82]. Ninety-five per-
cent of them are anaerobic bacteria and at least 1000 different
species have been listed to date [83]. The most frequently
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detected in the human gut are the phyla of the Firmicutes,
Bacteroidetes, Actinobacteria, Cyanobacteria, Fusobacteria,
Proteobacteria, and Verrucomicrobia [84]. Knowledge
concerning bacterial communities far outpaces that of the viral
and eukaryotic communities [85]. The observed ratio of 7–10
viral-like particles per microbial cell in environmental [86]
human samples [87] means that we could expect to find as
many as 1015 phages in the body, with the gut having the
highest abundance of viruses, 3 × 1012 [88]. The diversity of
the human virome is low. It is estimated that there are 1500
viral genotypes in a typical healthy, human virome [88].
Studies of the viral community in the human gut showed
Caudovirales to be prevalent [89]: Siphoviridae, Myoviridae,
Podoviridae, Microviridae [90, 91]. Eukaryotes that reside in
the human gut are distributed across the eukaryotic tree and
their relationship with the human host varies from parasitic to
opportunistic to commensal to mutualistic [92]. It has been
known that yeasts constitute part of the intestinal flora:
Candida spp. (C. parapsilosis, C. albicans, C. glabrata,
C. krusei, C. tropicalis) or Saccharomyces boulardii [92,
93]. Diverse eukaryotes inhabit the human gut, including pro-
tists and helminths [92].Many species of protists are commen-
sals and harmless, including Pentatrichomonas and
Entamoeba dispar [94]. Interestingly, available data suggest
that many common eukaryotic residents are commensals, but
are, in some cases, associated with gastrointestinal disorders
[5]. Good examples are Blastocystis sp. or Dientamoeba
fragilis [5, 95]. Other representative protists that are part of
the human gut eukaryome include: Enteromonas hominis,
Retortamonas intestinalis, Chilomastix mesnili, Entamoeba
hartmanni, Entamoeba nana, Entamoeba coli, Isospora belli,
Iodamoeba buetschi and Encephalitozoon cuniculi [5].
Pathogenicity is certainly the role for some intestinal protists,
such as Cryptosporidium spp., Entamoeba histolytica or
Giardia intestinalis [92], as well as for some helminths, such
as Ascaris lumbricoides and Strongyloides stercoralis [5].
The role of Blastocystis in the human gut: bad
and good sites
Blastocystis was first described more than 100 years ago,
but there are still many obscurities about its clinical sig-
nificance. It may colonize the bowels and is commonly
isolated in individuals with neither gastrointestinal com-
plaints nor symptoms [19, 47]. However, Blastocystis was
also identified as the only causative agent of gastrointes-
tinal or dermatological symptoms, such as abdominal
pain, diarrhea, nausea, vomiting, bloating, anorexia, or,
less commonly, urticaria, intense itching [56, 57], or iron
deficiency anemia [96–98].
As mentioned above, there can be several explanations for
Blastocystis pathogenicity. It may depend on the Blastocystis
subtype: different subtypes can excrete protease enzymes
which are able to take part in the induction of virulence [49,
99, 100]. Most Blastocystis isolates found in stool samples are
in cyst or vacuolar forms. The amoeboid form is rarely seen,
but is mostly associated with symptoms [3]. Therefore, amoe-
boid forms of Blastocystis are probably pathogenic. A large
number of the parasites in the intestine (>5 parasites per high-
power field) are also connected with gastrointestinal symp-
toms [1]. Human gut microbiota composition and the immune
system are also deciding agents in the pathogenicity and oc-
currence of the parasite. In immunocompromised individuals,
such as those with HIV infection, the prevalence reaches 38%
in developed countries [28], and an association with diarrhea
is suggested. The nutritional status of an individual may be
one of the most important risk factors for co-infection [3].
Children and the elderly are highly susceptible to
Blastocystis infection [20, 31], whereas research interestingly
showed that people aged 30–50 years old are mostly infected
[33]. Blastocystis can also have beneficial effects stemming
from its ability to modulate the host immune system. One
mechanism of action is the stimulation of mucus production,
via the cytokine IL-22, which alleviates symptoms of colitis,
improving gut health [101]. Perhaps Blastocystis is more com-
mon in healthy people because it helps maintain a healthy
mucus layer in the intestine, either directly or through interac-
tions with beneficial bacteria or the immune system [5].
Blastocystis have been shown to be more prevalent in patients
suffering from IBS [18, 102–106]. A 2014 study by
Nourrisson et al. [107] suggests that Blastocystismay be used
as an indicator of microbiota changes; a lower abundance of
Bifidobacterium spp. and Faecalibacterium prausnitzii were
reported to have protective and anti-inflammatory effects,
which could lead to intestinal dysbiosis and IBS. Nagel et al.
[108] confirmed these results in 2016. On the other hand, in
2016, Audebert et al. [109] suggested that colonization by
Blastocystis could be associatedwith a healthy gut microbiota.
Their study showed a higher bacterial diversity in
Blastocystis-colonized patients compared to that identified in
Blastocystis-free individuals. In Blastocystis-colonized pa-
tients, there was a higher abundance of the Clostridia class
and Ruminococcaceae and Prevotellaceae families, while
Enterobacteriaceae were enriched inBlastocystis-free patients.
The most recent results of the latest studies leave the pathoge-
nicity of Blastocystis still unclear and this is similar to the
chicken and egg question: which came first? It is still a mys-
tery. Is Blastocystis an agent of the gut dysbiosis and changing
the microbiotic diversity, or are the metabolic dysfunctions
and changes in the content of microbiota the reason for the
higher colonization by Blastocystis? There is a possibility that
some species of bacteria are triggering the protease activity of
Blastocystis, which causes the gastrointestinal symptoms. It
may also depend on parasitic subtype. To address this, further
studies in humans are required [109].
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The influence of different diets on Blastocystis
as compared to antibiotic treatment
Although many Blastocystis infections remain asymptom-
atic, recent data suggest that it is a frequent cause of
gastrointestinal symptoms in children and adults [110].
Many parasitologists insist that, when Blastocystis organ-
isms are present in large numbers in stool examination,
even without the presence of any other known bacterial,
viral, or parasitic infection, treatment should be proposed
[110, 111]. Therapy should be limited to patients with
relentless symptoms and a complete negative workup for
alternative etiologies. Several drugs have been used
against Blastocystis infection, the most common still be-
ing metronidazole (MTZ), as the first-line treatment,
followed by nitazoxanide (NTZ), trimethoprim–sulfa-
methoxazole (TMP-SMX), ketoconazole, and tinidazole
as secondary treatments. Studies have shown that, while
MTZ demonstrates effectiveness in some individuals
[112, 113], it has also been shown to exhibit side effects
and resistance in others [114, 115]. Most probably, it de-
pends on the Blastocystis subtypes. Girish et al. [116], in
2015, reported that STs 1, 3, and 5 are susceptible to
MTZ, but resistant to ketoconazole, even when high doses
were administrated. ST1 is also resistant to TMP-SMX in
lower doses, and ST3 to NTZ in lower doses [116].
Studies have shown STs 4 and 7 to be resistant to MTZ
[117]. This drug can cause undesirable side effects and
changes in the gut microbiota. Moreover, failures in treat-
ment are frequently reported [117–122]. Additionally, po-
tential carcinogenic, teratogenic, and embryotoxic effects
of metronidazole have been reported [123]. Therefore,
there is a need to develop safe and alternative antimicro-
bial agents, such as the use of medicinal plants, spices,
specific vegetables, or yeasts.
The number of trials, in vitro and in vivo, in which the
anti-Blastocystis efficacies of some local plants are
assessed have been on the rise lately [124]. Plants were
chosen for their antimicrobial activity and chemical com-
position. Garlic (Allium sativum) contains a wide range of
the thiosulfinates (e.g., allicin), which are responsible for
the antibacterial activity [125] related to the inhibition of
enzymes, including thiol in microorganisms [126, 127].
Moreover, allicin in the garlic acts by totally inhibiting
RNA synthesis and partially inhibiting DNA and protein
syn thes i s o f the paras i t e s [128] . Addi t iona l ly,
hexahydrocurcumin, a constituent isolated from ginger
(Zingiber officinale), might be effective in killing the par-
asites [129]. Yakoob et al. [130] in 2011 and Abdel-Hafeez
et al. [131] in 2015 proved activity against Blastocystis
with garlic extract in vitro as compared to the antimicrobial
drugs MTZ and NTZ, respectively. Interestingly, they also
tested the antiparasitic activity of ginger and had differing
results. As Yakoobs and colleagues [130] showed in their
study, Blastocystis STs 1 and 3 were not sensitive to ginger,
black pepper, or cumin when compared to garlic and MTZ.
According to the study of Abdel-Hafeez et al. [131], ginger
has the greatest effect on Blastocystis clinical isolates, but
onion (Allium cepa) or turmeric (Curcuma longa) do not
[131, 132]. Moreover, garlic and ginger decrease
malondialdehyde (MDA) production significantly. The al-
licin contained in garlic acts as an antioxidant by retrieving
reactive oxygen species (ROS), preventing lipid oxidation
and production of pro-inflammatory messengers [133].
Additionally, gingerol contained in ginger inhibits the
ascorbate/ferrous complex-induced lipid peroxidation
[134]. Dugasani et al. [135], in 2010, reported that
gingerols and shogaols are the most bioactive compounds
of ginger. Both garlic and ginger seem to be strong antiox-
idants inhibiting nitric oxide (NO) production [131, 135].
Intestinal NO increases upon Blastocystis infection as a
host defense mechanism of epithelial cells against parasites
[117, 131]. Mirza et al. [117], in 2011, suggested that
Blastocystis is susceptible to NO. Nitric oxide is important
in homeostasis and host defense; however, it may also lead
to cellular damage and gut barrier failure, as well as having
been involved in the pathogenesis of many inflammatory
and autoimmune diseases [136, 137]. Garlic and ginger
treatments significantly downregulated NO intestinal re-
lease [131]. This may be caused by a decrease in
Blastocystis loads in the intestine. Downregulation of
MDA and NO are important mechanisms of garlic- and
ginger-induced antiparasitic effects.
El Deeb et al. [138], in 2012, proved an inhibitory
effect of Ferula asafoetida (in both powder and oil form)
on Blastocystis ST3. Furthermore, asafetida exerted a det-
rimental effect on Blastocystis morphology, which was
especially obvious at higher concentrations. The viable
vacuolar forms which were typically seen before incuba-
tion with either powder or oil were replaced by more
granular forms, which lost viability over time and showed
a shriveled appearance [138]. Asafoetida consists princi-
pally of volatile oil (4–20%) with isobutyl propanyl disul-
f ide (C8H16S2) , res in (40–60%) wi th es ter of
asaresinotannol and free ferulic acid, and gum (∼25%)
with caffeic acid cinnamyl ester showing moderate activ-
ity for inhibiting LPS-induced nitric oxide production in
murine macrophage RAW264.7 cells [139]. Blastocystis
ST3 is also sensitive to Tongkat Ali (Eurycoma
longifolia), as Girish and colleagues proved in a study in
2015 [116]. Most likely, four compounds are responsible
for antiparasitic activity: 3,4-dihydrochaparrinone,
laurycolactone B, β-carboline-1-propionic acid, and
canthin-6-one. These compounds have previously been
proven to possess therapeutic properties [140, 141].
Recently, there have been many reports which have
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shown the inhibitory effect of herbal extracts and spices
on Blastocystis. Vital and Rivera [142], in 2009, proved
that ethanol extracts of leaves of Chromolaena odorata
and ethyl acetate extracts of stem bark of Uncaria
perrottetii inhibited Blastocystis growth and decreased
cell counts at 0.5 and 1.0% concentrations, respectively.
Furthermore, Özbílgín et al. [143], in a 2013 study, dem-
onstrated that the methanol extract of Achillea millefolium
gave promising results and could be used as an anti-
protozoal agent in the future, especially against
Blastocystis STs 1, 2, and 3. Also, El Wakil [144], in
2007, showed that an aqueous extract of Nigella sativa
significantly inhibits the growth of Blastocystis isolates.
In addition, some medicinal plants from Ghana and
Thailand showed high activity against Blastocystis [145,
146]. Similarly, supplementation with 600 mg emulsified
oil of Mediterranean oregano (Origanum vulgare) daily
lead to the complete disappearance of Blastocystis [147].
It is also suggested to use Saccharomyces boulardii to
cure Blastocystis infection [111]. Commensal yeasts act
as a regulator of homeostasis in the gut through
preventing the colonization of pathogenic agents on intes-
tinal mucosa and augmenting the local immune response
[148]. In a placebo-controlled study, it was found to be
more effective against Blastocystis when compared to
metronidazole [111].
Conclusions
Blastocystis sp. is a parasite which does not need to be cured
with the antibiotics that cause side effects, such as metronida-
zole (MTZ). Mainly, the choice of eradication depends on the
Blastocystis subtype, geographic region of occurrence, patho-
genicity, immune system of the host, human gut microbiota, or
chronic diseases, such as diabetes. Natural herbs, vegetables,
or spices as an alternative for blastocystosis treatment not only
reduce drug resistance, but also their side effects and the cost
of treatment, especially in developing countries. Special diets
are effective mainly by inhibiting parasitic enzyme activity,
RNA, DNA, and protein synthesis, and, also, nitric oxide
(NO) production. Moreover, commensal yeasts and bacteria
prevent the colonization of pathogenic agents on intestinal
mucosa and augment the local immune response. Certain spe-
cies of beneficial microorganisms can have a negative influ-
ence on parasites by producing molecules that trigger the im-
mune system, but they may also cause protease activity in
Blastocystis, leading to symptoms of infection. Further inves-
tigation needs to be done to identify the organic compounds
causing Blastocystis eradication. Research should address if
the treatment directly affects Blastocystis or if it acts by
destroying the bacterial flora necessary for its development,
or both. We would like to suggest for future research the
determination of whether Blastocystis is an agent changing
the human gut microbiota or the opposite; does the commen-
sal microbiota help the parasite to colonize the gastrointestinal
tract? These questions and many others still remain unclear.
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